Evaluation of Brain Atrophy in CIS Patients on Avonex

NCT ID: NCT01592474

Last Updated: 2014-07-09

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 180 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2005-10-31
• Study Completion Date: 2012-06-30

Brief Summary

The purpose of this study is

• To examine if Avaonex can delay the development of clinically definite multiple sclerosis.
• To investigate if Avonex can delay disability progression by slowing brain atrophy.

Detailed Description

• Multiple sclerosis (MS) is a chronic inflammatory disorder characterized by focal areas of demyelination in the central nervous system (CNS). MRI findings suggest that we should look at gray matter atrophy as a marker of the disease process in MS.
• Avonex is a proven effective disease-modifying treatment, which reduces total brain and GM atrophy and should be considered first-line therapy in patients with RRMS and CIS.
• The original SET study is an open-label observational study of high risk subjects after CIS for development of CDMS that will enroll 220 patients who have started Avonex immediately after their first clinical attack in Czech Republic, and are followed with clinical and MRI examinations for 4 years at 0, 6, 12, 24, 36 and 48 months. The clinical and MRI acquisition examinations of this study are conducted in Czech Republic.

Conditions

Multiple Sclerosis

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Eligibility Criteria

Inclusion Criteria

• MRI findings must reveal at least 2 hyperintense lesions on T2-WI or FLAIR images at first clinical onset
• CSF examination should confirm oligoclonal bands (examination must be done in an internationally approved lab and the CSF taken before the treatment of attack starts)
• Age 18 - 55 years
• Effective contraception in female patients of childbearing potential
• Kurtzke EDSS ≤ 3.5 at baseline
• Willingness to accept the plan of the study and compliance with the study
• Time from the beginning of first symptoms of CIS to baseline visit should not exceed 4 months (baseline MRI and baseline visit will be organized first 28 days after last steroid administration)
• CIS attack is treated by at least 3g of methylprednisolone without taper
• In case of severe attack 1 g of cyclophosphamide does not disqualify the patient from the study if first MRI and CSF examination was done before treatment administered
• No active major organ disease especially of hepatic or thyroid origin

Exclusion Criteria

• The clinical diagnosis of MS is definite (the second attack occurs before the baseline visit)
• Age less than 18 or more than 55
• Non-effective contraception method or pregnancy planning
• Active major organ disease, especially hepatic or endocrinologic
• Cooperation of the subject cannot be ensured
• Kurtzke EDSS higher than 3.5 at baseline

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Biogen

INDUSTRY

Sponsor Role: collaborator

Jacobs Neurological Institute

OTHER

Sponsor Role: collaborator

Charles University, Czech Republic

OTHER

Sponsor Role: collaborator

University at Buffalo

OTHER

Sponsor Role: lead

Responsible Party

Robert Zivadinov, MD, PhD

Director, Buffalo Neuroimaging Analysis Center, Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Robert Zivadinov, MD,PhD,FAAN

Role: PRINCIPAL_INVESTIGATOR

University at Buffalo

References

Ravano V, Andelova M, Fartaria MJ, Mahdi MFA, Marechal B, Meuli R, Uher T, Krasensky J, Vaneckova M, Horakova D, Kober T, Richiardi J. Validating atlas-based lesion disconnectomics in multiple sclerosis: A retrospective multi-centric study. Neuroimage Clin. 2021;32:102817. doi: 10.1016/j.nicl.2021.102817. Epub 2021 Sep 2.

Reference Type: DERIVED

PMID: 34500427 (View on PubMed)

Other Identifiers

SET

Identifier Type: -

Identifier Source: org_study_id